InCephalo

🗓 Founded 2021👥 15 employees💰 Last funded May 2023
Biotechnology🌐 incephalo.com
Website LinkedIn
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in InCephalo?
InCephalo has 1 investors on record on gritt.io, including 1 early-stage backers.
When did InCephalo last raise funding?
The most recent investment in InCephalo recorded on gritt.io was in May 2023.
When was InCephalo founded?
InCephalo was founded in 2021.
What industry is InCephalo in?
InCephalo operates in Biotechnology. Find similar Biotechnology investors on gritt.io.